CLNN (Clene Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CLNN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Arjun JJ Desai | Director | A | — | — |
| 2026-08-14 | Alison Mosca | Director | A | — | — |
| 2026-08-14 | Matthew Kiernan | Director | A | — | — |
| 2026-08-14 | Vallerie McLaughlin | Director | A | — | — |
| 2026-08-14 | Jonathon Gay | Director | A | — | — |
| 2026-08-14 | Shalom Jacobovitz | Director | A | — | — |
| 2026-08-14 | REED N WILCOX | Director | A | — | — |
| 2026-08-14 | DAVID J MATLIN | Director | A | — | — |
| 2026-08-06 | Chidozie Ugwumba | 10%+ Owner | J | — | — |
| 2026-08-06 | Chidozie Ugwumba | 10%+ Owner | J | — | — |
| 2026-06-15 | MORGAN R BROWN | Chief Financial Officer | A | — | — |
| 2026-06-15 | Mark Mortenson | Chief Science Officer | A | — | — |
| 2026-06-15 | Robert Dee Etherington | President & CEO | A | — | — |
| 2026-05-22 | Jonathon Gay | Director | A | — | — |
| 2026-05-22 | Matthew Kiernan | Director | A | — | — |
| 2026-05-22 | DAVID J MATLIN | Director | A | — | — |
| 2026-05-22 | Alison Mosca | Director | A | — | — |
| 2026-05-22 | Shalom Jacobovitz | Director | A | — | — |
| 2026-05-22 | Arjun JJ Desai | Director | A | — | — |
| 2026-05-22 | Vallerie McLaughlin | Director | A | — | — |
| 2026-05-22 | REED N WILCOX | Director | A | — | — |
| 2026-05-13 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-05-05 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-04-22 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-04-17 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-04-06 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-04-01 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-03-26 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-02-20 | REED N WILCOX | Director | A | — | — |
| 2026-02-20 | Alison Mosca | Director | A | — | — |
| 2026-02-20 | Matthew Kiernan | Director | A | — | — |
| 2026-02-20 | Vallerie McLaughlin | Director | A | — | — |
| 2026-02-20 | Arjun JJ Desai | Director | A | — | — |
| 2026-02-20 | Shalom Jacobovitz | Director | A | — | — |
| 2026-02-20 | DAVID J MATLIN | Director | A | — | — |
| 2026-02-20 | Jonathon Gay | Director | A | — | — |
| 2026-02-05 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-02-02 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-28 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-23 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-23 | Robert Dee Etherington | President & CEO | A | — | — |
| 2026-01-23 | MORGAN R BROWN | Chief Financial Officer | A | — | — |
| 2026-01-23 | Mark Mortenson | Chief Science Officer | A | — | — |
| 2026-01-21 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-16 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-13 | DAVID J MATLIN | Director | Buy | — | — |
| 2026-01-13 | Alison Mosca | Director | MIXED | — | — |
| 2026-01-12 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-07 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| 2026-01-02 | Chidozie Ugwumba | 10%+ Owner | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 477,824 | — |
| — | Director | 282,473 | — |
| — | 10%+ Owner | 103,417 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CLNN quote page; the site-wide leaderboard is on the insider transactions hub.